Skin cancer (all types): lines of therapy
3 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Prevention | Sun protection, avoiding sunbeds and treating actinic keratoses; regular skin checks for people at high risk, with dermoscopy and AI tools improving lesion triage. | 32 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Basal cell and squamous cell carcinoma | Surgical excision or Mohs surgery; topical or photodynamic therapy for superficial lesions; radiotherapy when surgery is unsuitable; hedgehog inhibitors for advanced basal cell carcinoma and cemiplimab or pembrolizumab for advanced squamous cell carcinoma. See the subtype pages. | 81 | ||
| All comers | Melanoma | Excision with margins by thickness, sentinel node biopsy, adjuvant PD-1 blockade or BRAF/MEK inhibitors for high-risk disease, and checkpoint immunotherapy or targeted therapy for advanced disease. See the melanoma page. | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.